BioSpace News Archive

ReCode Therapeutics today announced the closing of an $80 million Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.

ATUM’s Leap-In Transposase ® Technology Supports Successful AskGene Pharma IND Clearance in China

Imvax, Inc. today announced a poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C., from November 10-14, 2021.

Cedilla Therapeutics today revealed its two lead conditional inhibitor programs: an inhibitor of TEAD for the treatment of solid tumors, such as mesothelioma and certain squamous cell carcinomas; and a highly selective inhibitor of CDK2 for the treatment of multiple tumor types, including CDK4/6-resistant breast cancer, ovarian, uterine, stomach, and esophageal cancers.

Crinetics Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 7,576,000 shares of its common stock at a price to the public of $19.80 per share.

reMYND NV, a clinical stage company, is pleased to announce that it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in the 58 healthy volunteers in the single-ascending dose (SAD) phase.

Evelo Biosciences, Inc. today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, October 28, 2021, to report its third quarter 2021 financial results and discuss business highlights.

Zynerba Pharmaceuticals , Inc. today announced oral and poster presentations at the Society for Developmental & Behavioral Pediatrics Annual Meeting, being held virtually October 21-25, 2021, and the 68th American Academy of Child & Adolescent Psychiatry Annual Meeting

MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced the publication of research on a strain of Staphylococcus felis (S. felis C4) isolated from feline skin for the treatment of Methicillin-resistant Staphylococcus pseudintermedius (MRSP).

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today four presentations of preclinical data spanning its clinical-stage gene therapy program for mucopolysaccharidosis type II (MPS II, or Hunter syndrome), clinical-stage gene editing program for phenylketonuria (PKU), GTx-mAb program for paroxysmal nocturnal hemoglobinuria (PNH).